Surgalign — Investor Day (November 2020)
58 slides from Surgalign's investor day presentation, Nov 12, 2020

Slide 1: Virtual Investors' Day November 12, 2020
Exhibit 99.1 Virtual Investors’ Day November 12, 2020Exhibit 99.1 Virtual Investors’ Day November 12, 2020

Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s

Slide 3: Terry Rich, President & Chief Executive Officer
Terry Rich President & Chief Executive Officer 3Terry Rich President & Chief Executive Officer 3

Slide 4: Today's Agenda
Today’s Agenda Vision and Strategy — Terry Rich, CEO Functional Overviews - Products and Innovation — Doug Bireley, EVP, Marketing and R&D - Research, Clinical Affairs, Surgeon Education: G. Bryan Cornwall PhD, EVP, Research & Clinical Affairs - Commercial Strategy — Scott Durall, CCO & Enrico Sangi

Slide 5: CEO's View of Surgalign
CEO’s View of Surgalign Attracted by several things: - $125M revenue (2019) with broad portfolio to build on - Clean balance sheet to fuel strategic initiatives - Established International platform - Demonstrated ability to drive growth - Ingrained commitment to clinical data - Large, diverse distri

Slide 6: The Launch of Surgalign
The Launch of Surgalign We stood Surgalign up on July 20, 2020, with a mission to align with surgeons to improve patient lives by developing and delivering intelligent solutions for spine disorders. Nine weeks later, announced deal to acquire Holosurgical and its industry-redefining ARAI™ digital

Slide 7: CEO's Perspective on Progress – First 90 days
st CEO’s Perspective on Progress – 1 90 days Key accomplishments since becoming chief executive in July: Completed separation from OEM and established SRGA as a global pure-play spine company Navigated global COVID-19 business impact Built a world class leadership team Designed New Product Road Map

Slide 8: Surgalign Strategic Pillars
Surgalign Strategic Pillars Organically develop Acquire to drive Build and optimize new high-value clinically differentiation and scale, a global spine validated solutions that and add enabling infrastructure and will enhance standard technologies organization of careSurgalign Strategic Pillars Orga

Slide 9: Strategic Drivers: Win by Improving Patient Outcomes
STRATEGIC DRIVERS: WIN BY IMPROVING PATIENT OUTCOMES Embrace and partner with surgeon thought leaders Harness transformative, clinically-validated innovation Differentiate core and biomaterials products Lead the way in digital surgerySTRATEGIC DRIVERS: WIN BY IMPROVING PATIENT OUTCOMES Embrace and p

Slide 10: Proven Executive Leadership Team
Proven Executive Leadership Team Jon Singer Scott Durall Kris Siemionow Robert Watkins Chief Financial & Operating Chief Medical Officer Chief Commercial Officer Chief Technology Officer Officer 1998 Terry Rich President & CEO Josh DeRienzis G. Bryan Cornwall Doug Bireley Enrico Sangiorgio Renu Mene

Slide 11: Doug Bireley, EVP, Marketing and R&D
Doug Bireley, EVP, Marketing and R&D Portfolio overview Innovation road map 11Doug Bireley, EVP, Marketing and R&D Portfolio overview Innovation road map 11

Slide 12: Portfolio Assessment – Procedural Coverage
Portfolio Assessment – Procedural Coverage Strong product coverage by procedure type Balanced performance between U.S. / Intl. markets - Products cover 87% of core spine surgeries - Biomaterial offering covers 70% of spine-related uses GLOBAL SPINE HARDWARE MARKET, $12B SURGALIGN REVENUE 2020 YTD (D

Slide 13: Portfolio Assessment – Short Term Opportunities
Portfolio Assessment – Short Term Opportunities +14.5% +5.2% +20.0% 3D printed Ti Cage Market Biomaterials Market International Market 13Portfolio Assessment – Short Term Opportunities +14.5% +5.2% +20.0% 3D printed Ti Cage Market Biomaterials Market International Market 13

Slide 14: Pipeline Strategy
Pipeline Strategy Develop best-in-class posterior screw system Compete in traditional Lateral & ATP space Build upon our #2 position in SI Joint Expand differentiated BioMaterials portfolio Create seamless integration with Holosurgical Digital Platform Source: 2020 Orthostreams.com 14Pipeline Strate

Slide 15: Organizational Capabilities
Organizational Capabilities R&D Centers of Excellence in San Diego, CA & Wurmlingen, Germany Digital Surgery Innovation Center in Warsaw, Poland Harness new capabilities in artificial intelligence and predictive analytics via Holosurgical Digital Platform Align our efforts with the best surgeon KOLs

Slide 16: G. Bryan Cornwall, EVP, Research & Clinical Affairs
G. Bryan Cornwall, PhD, MBA, PEng EVP, Research & Clinical Affairs Research Strategy Surgeon Education 16G. Bryan Cornwall, PhD, MBA, PEng EVP, Research & Clinical Affairs Research Strategy Surgeon Education 16

Slide 17: Research Strategy
Research Strategy Positive MDR audit & certificate Focus on clinical outcomes: >100 coflex, HPS, Holo, etc. Leverage previous research experience for future Holosurgical Digital Platform publication strategy 17Research Strategy Positive MDR audit & certificate Focus on clinical outcomes: >100 coflex

Slide 18: Surgeon Education
Surgeon Education Design Center of Excellence in San Diego, CA Digital platform intuitive design Holosurgical Digital Platform driver for procedural solutions = very important for Surgeon Education & Clinical Research 18Surgeon Education Design Center of Excellence in San Diego, CA Digital platform

Slide 19: Commercial – Scott Durall, Chief Commercial Officer
Commercial Scott Durall, Chief Commercial Officer 19Commercial Scott Durall, Chief Commercial Officer 19

Slide 20: Commercial Strategy – Current
Commercial Strategy CURRE NT Top-10 market share Pure-play, standalone spine company Broad hospital/IDN/GPO contractual access Multiple specialized sales teams Separate/conflicting distribution channels Product portfolio gaps 20Commercial Strategy CURRE NT Top-10 market share Pure-play, standalone s

Slide 21: Commercial Strategy – Future
Commercial Strategy F UT URE Salesforce expansion, integration & alignment Surgeon & distributor penetration New product launches Biomaterials Ti Plus Interbodies ASC/outpatient procedural shift 21Commercial Strategy F UT URE Salesforce expansion, integration & alignment Surgeon & distributor penetr

Slide 22: Commercial Strategy
Commercial Strategy Direct-to-Surgeon engagement - Digital Surgery Education & Training program o Comprehensive procedural solutions Full-line Distributors partners Expanded Hospital Access & Committed Purchasing Agreements 22Commercial Strategy Direct-to-Surgeon engagement - Digital Surgery Educati

Slide 23: Commercial – Enrico Sangiorgio, EVP International
Commercial Enrico Sangiorgio, EVP International 23Commercial Enrico Sangiorgio, EVP International 23

Slide 24: International Business Outlook
International Business Outlook PRIORITY MARKETS CAN DELIVER: EUROPEAN OPERATIONS Warsaw • Poland o Double-digit growth Holosurgical Augmented Reality & Artificial Intelligence Healthy contribution margins Key Target Markets - Germany, UK, Italy, Spain, Australia, - Poland, Belgium, Taiwan, China, Vi

Slide 25: Optimized Sales Channel with Unique Product Offering
Optimized Sales Channel with unique product offering Fully direct: Germany, Poland and Belgium Semi-direct: UK, Spain, Italy and Australia Stocking distributors for rest of OUS 25 HPS 2.0 STREAMLINE F FORTILINK INTERBODY WITH TiPLUSOptimized Sales Channel with unique product offering Fully direct: G

Slide 26: Near Term Opportunities
Near term opportunities 11 Key product launches between Q4 2020 and Q2 2021 - HPS 2.0 dynamic hybrid system - Streamline F both MIS and Open - TiPlus range - Tetrafuse (CE pending) - Streamline OCT (CE pending) Operational growth enablers - Complete unified Sales Force in Germany, Poland, Belgium an

Slide 27: Dr. Kris Siemionow – HOLO Overview
Dr. Kris Siemionow, MD, PhD Holosurgical Co-Founder HOLO Overview 27Dr. Kris Siemionow, MD, PhD Holosurgical Co-Founder HOLO Overview 27

Slide 28: HoloSurgical – A Digital Surgery Company Focused on Spine
HoloSurgical - A Digital Surgery Company Focused on Spine We have developed an AI-based platform technology applicable across ALL of orthopedics, soft tissue, and general surgery *Holosurgical Digital Platform and ARAI Technology have not been evaluated by the FDA 28HoloSurgical - A Digital Surgery

Slide 29: HoloSurgical – A Quick History
HoloSurgical – A Quick History In 2013 we started looking for better ways of doing CAS A quote from a surgeon in the audience really stuck with me: “Robots are blind and dumb so why would I want to use one” -Anonymous Spine Surgeon *Holosurgical Digital Platform and ARAI Technology have not been eva

Slide 30: Evolution of Surgery
Evolution of Surgery The main barriers to the development of next generation MIS systems are limited visualization and a lack of intelligence, restricting functionality SURGERY 4.0 and prolonging surgery time. (Intelligent Surgery) Smart Augmented Instruments / OPEN SURGERY MIS & Navigation ROBOTS R

Slide 31: Holosurgical: Free Standing Surgical Guidance Platform
Holosurgical: Free Standing Surgical Guidance Platform The Holosurgical System is an advanced surgical guidance platform that combines: o 3D visualization o data analytics o artificial intelligence in order to: o improve outcomes o reduce surgical time o decrease complications *Holosurgical Digital

Slide 32: HoloSurgical = we taught the computer anatomy
HoloSurgical = we taught the computer anatomyHoloSurgical = we taught the computer anatomy

Slide 33: Once you teach the computer anatomy
Once you teach the computer anatomyOnce you teach the computer anatomy

Slide 34: Everything is possible.
Everything is possible.Everything is possible.

Slide 35: Augmented Reality, Predictive Analytics, Smart Instruments
AUGMENTED REALITY PREDICTIVE ANALYTICS AUTONOMOUS PLANNING C SMART INSTRUMENTS AUTONOMOUS GUIDANCE PERSONALIZED 3D PRINTING D IAG N O STI C S SMART ROBOTSAUGMENTED REALITY PREDICTIVE ANALYTICS AUTONOMOUS PLANNING C SMART INSTRUMENTS AUTONOMOUS GUIDANCE PERSONALIZED 3D PRINTING D IAG N O STI C S SMAR

Slide 36: Holosurgical Solutions: Complete Continuum of Care
Holosurgical Solutions: Complete Continuum of Care P REOP E R AT I V E I N T RAO PE RAT I V E P OSTOP E RAT I V E OUTPATIENT SOLUTIONS OUTPATIENT SOLUTIONS SOLU T ION S Diagnostics and Analytics Diagnostics and Analytics MRI/CT/Xray MRI/CT/Xray *Holosurgical Digital Platform and ARAI Technology have

Slide 37: HOLO Provides Keys to Digital Surgery Capability
HOLO PROVIDES KEYS TO DIGITAL SURGERY 5 CAPABILITY 1. Automatic Image Processing/Segmentation 2. Smart Instruments 3. Augmented Reality + Advanced Visualization 4. Patient Specific Procedures 5. Artificial Intelligence + Predictive Analytics *Holosurgical Digital Platform and ARAI Technology have no

Slide 38: Automatic Image Processing/Segmentation
Automatic Image Processing/Segmentation 1 Autonomous Spine Level Identification and Separation - Driven by Machine Learning Algorithms* Advantages of AI algorithms at work - Algorithm learned how to identify spinal levels o Automatically recognizes cervical, thoracic, lumbar segments o Automatically

Slide 39: Smart Instruments
Smart Instruments 2 Laminectomy + Smart Burr Pre Resection Post Resection Stop Stop Computer simulated resection planes *Holosurgical Digital Platform and ARAI Technology have not been evaluated by the FDA 40Smart Instruments 2 Laminectomy + Smart Burr Pre Resection Post Resection Stop Stop Computer

Slide 40: Augmented Reality + Advanced Visualization
Augmented Reality + Advanced Visualization 3 TM TM ARAI System Summary: “Smart X-Ray Vision ” Smart Guidance X-Ray Vision (Artificial (Augmented Intelligence Reality Software) Software) *Holosurgical Digital Platform and ARAI Technology have not been evaluated by the FDA 41Augmented Reality + Advanc

Slide 41: Patient Specific Procedures via Robust Software Application
Patient Specific Procedures via Robust Software Application 4 Scoliosis Segmentation Revolutionize Personalized 3D Printing Bone Density Disc Segmentation Congenital Scoliosis Idiopathic Scoliosis Extra bone! 42Patient Specific Procedures via Robust Software Application 4 Scoliosis Segmentation Revo

Slide 42: Artificial Intelligence + Predictive Analytics
Artificial Intelligence + Predictive Analytics 5 AI has potential for a wide range of applications: Case specific implant delivery Auto identifies implant size, bone density, volume, parameters Reduces wrong level surgery Guides smart instrument on where to perform procedure Essential for personaliz

Slide 43: Surgical Workflow
Surgical Workflow There are multiple options for seamless integration into the surgeon’s existing workflow AR-Based 3D Autonomous Autonomous Pre-op Intra-op Surgery with OPTION 1 Software Registration and Scan Scan Autonomous Planning Anatomy I.D. Guidance AR-Based 3D Autonomous Autonomous Surgery w

Slide 44: HoloSurgical = we taught the computer anatomy
HoloSurgical = we taught the computer anatomyHoloSurgical = we taught the computer anatomy

Slide 45: Once you teach the computer anatomy
Once you teach the computer anatomyOnce you teach the computer anatomy

Slide 46: Everything is possible
Everything is possibleEverything is possible

Slide 47: Everything is possible
Everything is possibleEverything is possible

Slide 48: Everything is possible
Everything is possibleEverything is possible

Slide 49: Everything is possible
Everything is possibleEverything is possible

Slide 50: Everything is possible
Everything is possibleEverything is possible

Slide 51: Jon Singer – Financial Overview
Jon Singer Chief Financial & Operating Officer Financial Overview 52Jon Singer Chief Financial & Operating Officer Financial Overview 52

Slide 52: Key Accomplishments for 2020
Key Accomplishments for 2020 Completed separation from OEM and established SRGA as a global pure-play spine company Navigated global COVID-19 business impact Built a world class leadership team Designed New Product Road Map Initiated Salesforce integration Acquired a leading position in the future o

Slide 53: Milestones for 2021
Milestones for 2021 Complete Salesforce integration and continue optimization Accelerate our innovation agenda FDA Clearance of Holo technology Launch multiple IRB sites to build clinical evidence and to continue development of intelligent surgery Return to growth – position us for attractive double

Slide 54: Multiple Drivers of Growth
Multiple Drivers of Growth Portfolio refresh and new product introductions Reinforce commitment to clinical evidence Strengthen distributor integration and leverage superior contractual access Leverage international platform Holo launch, placements and product pull-through Opportunistic distribution

Slide 55: Key Financial Metrics
Key Financial Metrics REVENUE BY PRODUCT CATEGORY SURGALIGN REVENUE 2020 YTD (HARDWARE VS. BIOLOGICS, MRQ) (DOMESTIC VS INTERNATIONAL, MRQ) Domestic Hardware 83% 77% Biologics International 23% 17% 56Key Financial Metrics REVENUE BY PRODUCT CATEGORY SURGALIGN REVENUE 2020 YTD (HARDWARE VS. BIOLOGICS

Slide 56: 2023 Targeted Metrics
2023 Targeted Metrics DOUBLE 10-13% 75% >50% ~ DIGIT R&D as a Revenue Growth Gross Margin Vitality Index % of Revenue 572023 Targeted Metrics DOUBLE 10-13% 75% >50% ~ DIGIT R&D as a Revenue Growth Gross Margin Vitality Index % of Revenue 57

Slide 57: Q & A
Q & A 58Q & A 58

Slide 58: Surgalign Spine Technologies
Source: SEC EDGAR · 8-K filed Nov 12, 2020
